Next Article in Journal
Integrated Analysis of the Safety Experience in Adults with the Bivalent Respiratory Syncytial Virus Prefusion F Vaccine
Previous Article in Journal
Immunogenicity, Safety, and Protective Efficacy of Mucosal Vaccines Against Respiratory Infectious Diseases: A Systematic Review and Meta-Analysis
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Vaccines
Volume 13
Issue 8
10.3390/vaccines13080826
vaccines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite
Correction to Vaccines 2025, 13(5), 467.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Huang et al. The Safety and Immunogenicity of a Quadrivalent Influenza Subunit Vaccine in Healthy Children Aged 6–35 Months: A Randomized, Blinded and Positive-Controlled Phase III Clinical Trial. Vaccines 2025, 13, 467

by
Lili Huang
1,†,
Guangfu Li
2,†,
Yuhui Zhang
2,
Xue Zhao
2,
Kai Wang
2,
Chunyu Jia
2,
Wei Zhang
1,
Jiebing Tan
1,
Xiaofen Chen
2,
Qin Li
2,
Hongyan Jiang
2,
Rui An
2,
Wenna Leng
2,
Yongli Yang
3,
Youcai An
2,
Yanxia Wang
1,* and
Yaodong Zhang
2,*
1
Henan Provincial Centre for Disease Control and Prevention, Zhengzhou 450016, China
2
Ab&B Bio-Tech Co., Ltd. JS, Taizhou 225300, China
3
Department of Epidemiology and Public Health, College of Public Health, Zhengzhou University, Zhengzhou 450001, China
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Vaccines 2025, 13(8), 826; https://doi.org/10.3390/vaccines13080826 (registering DOI)
Submission received: 22 July 2025 / Accepted: 29 July 2025 / Published: 1 August 2025
Versions Notes
The authors would like to make the following corrections to this published paper [1].
First, the formulation of QIV-Split-LD was incorrectly described. All underlying data, analyses, and conclusions remain accurate.
A correction has been made to Section 2. Methods, Sub-section 2.3 Vaccines, Paragraph 2:
“QIV-Sub-HD is formulated as 0.5 mL per dose, with 15 µg of hemagglutinin for each influenza virus strain included. Both QIV-Sub-LD and the QIV-Split-LD are formulated as 0.25 mL per dose, with 7.5 µg of hemagglutinin for each influenza virus strain included.”
Second, the original sentence incorrectly attributed the significantly higher runny nose rate to the QIV-Sub-HD group instead of the QIV-Sub-LD group, based on the presented data and statistical analysis (QIV-Sub-LD: 10.39% vs QIV-Split-LD: 7.82%), it is the QIV-Sub-LD group that demonstrated the significantly higher rate relative to QIV-Split-LD. This is solely a textual error; the underlying data, statistics, tables, and scientific conclusions are correct.
A correction has been made to Section 3. Results, Sub-section 3.2 Safety, Paragraph 3:
“The runny nose rates related to vaccination were 7.82% (6.17–9.74%), 10.39% (8.50–12.54%) and 7.27% (5.68–9.15%), respectively, with runny nose rate in the QIV-Sub-LD group being significantly higher than in QIV-Split-LD.”
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Huang, L.; Li, G.; Zhang, Y.; Zhao, X.; Wang, K.; Jia, C.; Zhang, W.; Tan, J.; Chen, X.; Li, Q.; et al. The Safety and Immunogenicity of a Quadrivalent Influenza Subunit Vaccine in Healthy Children Aged 6–35 Months: A Randomized, Blinded and Positive-Controlled Phase III Clinical Trial. Vaccines 2025, 13, 467. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Huang, L.; Li, G.; Zhang, Y.; Zhao, X.; Wang, K.; Jia, C.; Zhang, W.; Tan, J.; Chen, X.; Li, Q.; et al. Correction: Huang et al. The Safety and Immunogenicity of a Quadrivalent Influenza Subunit Vaccine in Healthy Children Aged 6–35 Months: A Randomized, Blinded and Positive-Controlled Phase III Clinical Trial. Vaccines 2025, 13, 467. Vaccines 2025, 13, 826. https://doi.org/10.3390/vaccines13080826

AMA Style

Huang L, Li G, Zhang Y, Zhao X, Wang K, Jia C, Zhang W, Tan J, Chen X, Li Q, et al. Correction: Huang et al. The Safety and Immunogenicity of a Quadrivalent Influenza Subunit Vaccine in Healthy Children Aged 6–35 Months: A Randomized, Blinded and Positive-Controlled Phase III Clinical Trial. Vaccines 2025, 13, 467. Vaccines. 2025; 13(8):826. https://doi.org/10.3390/vaccines13080826

Chicago/Turabian Style

Huang, Lili, Guangfu Li, Yuhui Zhang, Xue Zhao, Kai Wang, Chunyu Jia, Wei Zhang, Jiebing Tan, Xiaofen Chen, Qin Li, and et al. 2025. "Correction: Huang et al. The Safety and Immunogenicity of a Quadrivalent Influenza Subunit Vaccine in Healthy Children Aged 6–35 Months: A Randomized, Blinded and Positive-Controlled Phase III Clinical Trial. Vaccines 2025, 13, 467" Vaccines 13, no. 8: 826. https://doi.org/10.3390/vaccines13080826

APA Style

Huang, L., Li, G., Zhang, Y., Zhao, X., Wang, K., Jia, C., Zhang, W., Tan, J., Chen, X., Li, Q., Jiang, H., An, R., Leng, W., Yang, Y., An, Y., Wang, Y., & Zhang, Y. (2025). Correction: Huang et al. The Safety and Immunogenicity of a Quadrivalent Influenza Subunit Vaccine in Healthy Children Aged 6–35 Months: A Randomized, Blinded and Positive-Controlled Phase III Clinical Trial. Vaccines 2025, 13, 467. Vaccines, 13(8), 826. https://doi.org/10.3390/vaccines13080826

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop